Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy
A legfontosabb adatok
- Ki végzi
- University of Vermont
- Hol
- Burlington (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Résztvevők
- 22 fő vett részt
- Kezdés
- 2020. márc. 1.
- Befejezés
- 2024. jan. 1.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- Fluciclovine PET/CT using a digital PET/CT
- A regiszteradat frissítve
- 2024. január 24.
- Miért állt le
- Lack of efficacy of Axumin and resultant lack of interest in recruitment. FDA approval of PSMA also hampered enrollment.
Ki vehet részt
- Életkor
- 40 év felett
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 6 feltétel megnézéseKevesebb
Ki vehet részt
- Prostatectomy patients with previously undetectable PSA and subsequent biochemical recurrence defined by PSA between 0.2 ng/ml and 1.0 ng/ml within 90 days prior to Fluciclovine scan
- Age >40
- Ability to provide informed consent
Ki nem vehet részt
- Anti Androgen treatment in the 6 months prior to enrollment
- History of allergic reaction to Fluciclovine
- Any patient whose body habitus, as determined by radiology personnel, will effectively inhibit the ability to obtain PET/CT imaging or will interfere with the images so as to make them clinically uninterpretable
Helyszínek itt: Egyesült Államok
- UVM Medical CenterBurlington, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Fluciclovine F18 (Axumin) has been demonstrated to provide good delineation of recurrence of prostate cancer after definitive therapies. Fluciclovine in conjunction with the high-resolution digital Vereos (Phillips) PET-CT scanner may detect low volume recurrence in the prostatectomy bed or metastatic site (s).
A teljes eredeti leírásKevesebb
20-40 % of men will suffer a biochemical recurrence of their prostate cancer after radical prostatectomy, depending on their final pathological staging, defined as a rising PSA > 0.2 ng/ml.
The ability to more accurately diagnose local recurrence (i.e. pelvis) or oligometastasis may lead to the opportunity of precise therapy of these sites with more durable cancer responses, less morbidity and potential cure in selective men after Radical Prostatectomy.
The ability to diagnose widespread metastatic Prostate Cancer after Radical Prostatectomy, or disease that is inaccessible to local selective therapies would spare these men the cost and morbidity of inappropriate therapy.
The diagnosis of true stage D0 Prostate Cancer (No objective evidence of metastases) in men after Radical Prostatectomy would yield improved overall and disease specific survival if Androgen Deprivation Therapy was initiated at its earliest stage. This would also obviate the need for inappropriate local therapies (i.e. pelvic radiotherapy).
The aim is to compare the detection rate of standard of care (CT Pelvis/Abdomen, MR Pelvis, Bone Scan) with Fluciclovine PET/CT performed on the Vereos Philips Scanner. The study aims to compare the performance of Digital (high resolution) PET to CT/MRI/Bone scan rather than analog (lower resolution) PET. Prior studies have tested analog PET compared to other modalities. One could make an inference that if our study's Digital PET performs better than the performance of Analog PET in those studies, then Digital PET should have a better detection rate than Analog PET. However, investigators are not making a direct comparison between digital and Analog in our comparison.
A vizsgálat csoportja
- Group
All patients receiving SOC imaging and Axumin PET scans.
Kezelés: Fluciclovine PET/CT using a digital PET/CT
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) PET/CT Utilizing the High Resolution Digital Philips Vereos Scanner, in Patients With Biochemical Recurrence After Radical Prostatectomy
- A regiszteradat frissítve
- 2024. január 24.